Eli Price To Sales Ratio from 2010 to 2024
LLY Stock | USD 733.51 8.64 1.19% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 15.37721166 | Current Value 16.15 | Quarterly Volatility 4.64867282 |
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli main balance sheet or income statement drivers, such as Depreciation And Amortization of 994.5 M, Interest Expense of 327.9 M or Total Revenue of 35.8 B, as well as many exotic indicators such as Price To Sales Ratio of 16.15, Dividend Yield of 0.0074 or PTB Ratio of 51.15. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
Eli | Price To Sales Ratio |
Latest Eli Lilly's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Eli Lilly and over the last few years. Price to Sales Ratio is figured by comparing Eli Lilly stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Eli Lilly sales, a figure that is much harder to manipulate than other Eli Lilly and multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period. Eli Lilly's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 20.94 X | 10 Years Trend |
|
Price To Sales Ratio |
Timeline |
Eli Price To Sales Ratio Regression Statistics
Arithmetic Mean | 6.27 | |
Geometric Mean | 4.99 | |
Coefficient Of Variation | 74.13 | |
Mean Deviation | 3.58 | |
Median | 4.48 | |
Standard Deviation | 4.65 | |
Sample Variance | 21.61 | |
Range | 14.2438 | |
R-Value | 0.89 | |
Mean Square Error | 4.67 | |
R-Squared | 0.80 | |
Slope | 0.93 | |
Total Sum of Squares | 302.54 |
Eli Price To Sales Ratio History
About Eli Lilly Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Eli Lilly income statement, its balance sheet, and the statement of cash flows. Eli Lilly investors use historical funamental indicators, such as Eli Lilly's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Eli Lilly investors may use each financial statement separately, they are all related. The changes in Eli Lilly's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eli Lilly's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eli Lilly Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Price To Sales Ratio | 15.38 | 16.15 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Eli Lilly Correlation against competitors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Transaction History View history of all your transactions and understand their impact on performance | |
Stocks Directory Find actively traded stocks across global markets |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.79 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.